International Journal of Pharma and Bio Sciences
ijpbs.net
editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com
10.22376/ijpbs.2019.10.1.p1-12
Volume 6 Issue 4
2015 (October - December)
A STUDY OF AVAILABLE BRANDS OF ANTIVIRAL AND ANTITUBERCULOSIS DRUGS IN INDIA
During the last few decades the continuous emergence and re-emergence of viruses, due to evolution of virus, viral latency, improper diagnosis, viral resistance, toxicity and immunosuppression caused by antivirals, is a serious public health concern. There has been tremendous progress in understanding of molecular mechanisms and genetic basis of diseases and virus in the recent years. Many new drugs have been developed and a lot more are in the process of development. Still, we are struggling against viruses and lack foolproof antiviral therapies against them. In order to intensify our fight against deadly disease tuberculosis, we need to further strengthen our surveillance programs to accurately estimate the burden of all kinds of TB (childhood, HIV/TB, MDR-TB). There is a dire need to regulate the rational use of first- and second-line anti-TB drugs. They should absolutely not be sold as lessThan i greaterThan over the counter lessThan /i greaterThan drugs. More than 1.5 million people currently receive free drugs at the 13,000 Indian government centres across the country. The Indian government's Revised National TB Control Programme (RNTCP) started in India in 1997, extend out a helping hand to all people diagnosed with TB, and in addition, provide better quality services and improve on therapy for these patients.
SUNISHA KULKARNI
emergence of viruses, antiviral, deadly disease tuberculosis, anti-TB drugs, etc.
178-185